In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.
Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.
There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.